Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience

Uri Kopylov, Irit Avni-Biron, Yulia Ron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Doron Schwartz, Eran Zittan, Michal Openhaim, Henit Yanai, Nitsan Maharshak, Ariella Bar Gil Shitrit, Timna Naftali, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce. Aims: To describe the effectiveness and safety of VDZ in maintenance treatment of IBD. Methods: A multicenter retrospective national study. The primary outcome of was clinical response at week 52; main secondary aims included clinical remission at week 52, rates of secondary loss of response and treatment discontinuation. Results: We included 193 (133—CD; 60—UC) patients from 9 Israeli IBD centers. At week 52, response was observed in 62/133 (46.7%) CD patients, including 28 (21%) in clinical remission; 71 (53.3%) discontinued treatment or did not respond. For UC, response at week 52 was observed in 27/60 (45%), including 20 (33%) in clinical remission; 33 (55%) discontinued treatment or did not respond. Secondary non-response by week 52 occurred in 19.4% and 23.5% of week 14 responders in CD and UC, respectively. Week 14 response was associated with treatment continuation at week 52: no predictors of secondary loss of response were identified. VDZ is safe and effective for maintenance of response and remission in IBD; week 14 response is positively associated with long-term response in both UC and CD.

Original languageEnglish
Pages (from-to)68-74
Number of pages7
JournalDigestive and Liver Disease
Volume51
Issue number1
DOIs
StatePublished - Jan 2019

Keywords

  • Crohn's disease
  • Ulcerative colitis
  • Vedolizumab

Fingerprint

Dive into the research topics of 'Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience'. Together they form a unique fingerprint.

Cite this